Emerging treatments and therapeutic targets for tuberous sclerosis complex in children

References

• Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet. 2008;372:657–668.
   PubMed Web of Science ®Google Scholar
• Henske EP, Jóźwiak S, Kingswood JC, et al. Tuberous sclerosis complex. Nat Rev Dis Prim. 2016;2:16035.
   PubMed Web of Science ®Google Scholar
• Ebrahimi-Fakhari D, Mann LL, Poryo M, et al. Incidence of tuberous sclerosis and age at first diagnosis: new data and emerging trends from a national, prospective surveillance study. Orphanet J Rare Dis. 2018;13:117.
   PubMed Web of Science ®Google Scholar
• Caban C, Khan N, Hasbani DM, et al. Genetics of tuberous sclerosis complex: implications for clinical practice. Appl Clin Genet. 2017;10:1–8.
   PubMedGoogle Scholar
• Northrup H, Krueger DA, Northrup H, et al. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 international tuberous sclerosis complex consensus conference. Pediatr Neurol. 2013;49:243–254.
   PubMed Web of Science ®Google Scholar
• Yang P, Cornejo KM, Sadow PM, et al. Renal cell carcinoma in tuberous sclerosis complex. Am J Surg Pathol. 2014;38:895–909.
   PubMed Web of Science ®Google Scholar
• Bjornsson J, Short MP, Kwiatkowski DJ, et al. Tuberous sclerosis-associated renal cell carcinoma. Clinical, pathological, and genetic features. Am J Pathol. 1996;149:1201–1208.
   PubMed Web of Science ®Google Scholar
• Thompson RH, Ordonez MA, Iasonos A, et al. Renal cell carcinoma in young and old patients – is there a difference? J Urol. 2008;180:1262–1266; discussion 1266.
   Web of Science ®Google Scholar
• Józwiak S, Schwartz RA, Janniger CK, et al. Usefulness of diagnostic criteria of tuberous sclerosis complex in pediatric patients. J Child Neurol. 2000;15:652–659.
   PubMed Web of Science ®Google Scholar
• Chu-Shore CJ, Major P, Camposano S, et al. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia. 2009;51:1236–1241.
   PubMed Web of Science ®Google Scholar
• Firkin AL, Marco DJT, Saya S, et al. Mind the gap: multiple events and lengthy delays before presentation with a “first seizure”. Epilepsia. 2015;56:1534–1541.
   PubMed Web of Science ®Google Scholar
• de Groen A-EC, Bolton J, Bergin AM, et al. The evolution of subclinical seizures in children with tuberous sclerosis complex. J Child Neurol. 2019;883073819860640.
   Web of Science ®Google Scholar
• Savini MN, Mingarelli A, Vignoli A, et al. Ictal signs in tuberous sclerosis complex: clinical and video-EEG features in a large series of recorded seizures. Epilepsy Behav. 2018;85:14–20.
   PubMed Web of Science ®Google Scholar
• Brodie MJ. Antiepileptic drug therapy the story so far. Seizure. 2010;19:650–655.
   PubMed Web of Science ®Google Scholar
• Capal JK, Bernardino-Cuesta B, Horn PS, et al. Influence of seizures on early development in tuberous sclerosis complex. Epilepsy Behav. 2017;70:245–252.
   PubMed Web of Science ®Google Scholar
• Benova B, Petrak B, Kyncl M, et al. Early predictors of clinical and mental outcome in tuberous sclerosis complex: a prospective study. Eur J Paediatr Neurol. 2018;22:632–641.
   PubMed Web of Science ®Google Scholar
• Bolton PF, Clifford M, Tye C, et al. Intellectual abilities in tuberous sclerosis complex: risk factors and correlates from the tuberous sclerosis 2000 study. Psychol Med. 2015;45:2321–2331.
   PubMed Web of Science ®Google Scholar
• Pitkänen A, Lukasiuk K, Dudek FE, et al. Epileptogenesis. Cold Spring Harb Perspect Med. 2015;5:a022822.
   PubMed Web of Science ®Google Scholar
• Wu JY, Peters JM, Goyal M, et al. Clinical electroencephalographic biomarker for impending epilepsy in asymptomatic tuberous sclerosis complex infants. Pediatr Neurol. 2016;54:29–34.
   PubMed Web of Science ®Google Scholar
• Domańska-Pakieła D, Kaczorowska M, Jurkiewicz E, et al. EEG abnormalities preceding the epilepsy onset in tuberous sclerosis complex patients – a prospective study of 5 patients. Eur J Paediatr Neurol. 2014;18:458–468.
   PubMed Web of Science ®Google Scholar
• Słowińska M, Jóźwiak S, Peron A, et al. Early diagnosis of tuberous sclerosis complex: a race against time. How to make the diagnosis before seizures? Orphanet J Rare Dis. 2018;13:25.
   PubMed Web of Science ®Google Scholar
• Jóźwiak S, Kotulska K, Domańska-Pakieła D, et al. Antiepileptic treatment before the onset of seizures reduces epilepsy severity and risk of mental retardation in infants with tuberous sclerosis complex. Eur J Paediatr Neurol. 2011;15:424–431.
   PubMed Web of Science ®Google Scholar
• Jozwiak S, Słowińska M, Borkowska J, et al. Preventive antiepileptic treatment in tuberous sclerosis complex: long-term, prospective trial. Pediatr Neurol. 2019. (23.07.19):[in press].
   Google Scholar
• EPISTOP [Internet]. Off. press release. 2019 [cited 2019 Jun 13]. Available from: http://www.epistop.eu/index.php/news/192-closing-conference-april-4-in-warsaw
   Google Scholar
• Curatolo P, Nabbout R, Lagae L, et al. Management of epilepsy associated with tuberous sclerosis complex: Updated clinical recommendations. Eur J Paediatr Neurol. 2018;22:738–748.
   PubMed Web of Science ®Google Scholar
• Curatolo P, Jóźwiak S, Nabbout R, et al. Management of epilepsy associated with tuberous sclerosis complex (TSC): clinical recommendations. Eur J Paediatr Neurol. 2012;16:582–586.
   PubMed Web of Science ®Google Scholar
• Reddy DS, Golub VM. The pharmacological basis of cannabis therapy for epilepsy. J Pharmacol Exp Ther. 2016;357:45–55.
   PubMed Web of Science ®Google Scholar
• Serra I, Scheldeman C, Bazelot M, et al. Cannabidiol modulates phosphorylated rpS6 signalling in a zebrafish model of tuberous sclerosis complex. Behav Brain Res. 2019;363:135–144.
   PubMed Web of Science ®Google Scholar
• Shrivastava A, Kuzontkoski PM, Groopman JE, et al. Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy. Mol Cancer Ther. 2011;10:1161–1172.
   PubMed Web of Science ®Google Scholar
• Solinas M, Massi P, Cinquina V, et al. Cannabidiol, a non-psychoactive cannabinoid compound, inhibits proliferation and invasion in U87-MG and T98G glioma cells through a multitarget effect. Velasco G, editor. PLoS One. 2013;8:e76918.
   PubMed Web of Science ®Google Scholar
• Velasco G, Sánchez C, Guzmán M. Anticancer mechanisms of cannabinoids. Curr Oncol. 2016;23:S23–32.
   PubMed Web of Science ®Google Scholar
• Thiele EA, Marsh ED, French JA, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391:1085–1096.
   PubMed Web of Science ®Google Scholar
• Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the dravet syndrome. N Engl J Med. 2017;376:2011–2020.
   PubMed Web of Science ®Google Scholar
• Hess EJ, Moody KA, Geffrey AL, et al. Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex. Epilepsia. 2016;57:1617–1624.
   PubMed Web of Science ®Google Scholar
• GW pharmaceuticals reports positive phase 3 pivotal trial results for EPIDIOLEX® (cannabidiol) oral solution in patients with seizures associated with tuberous sclerosis complex [Internet]. 2019 [cited 2019 July 8]. Available from: http://ir.gwpharm.com/news-releases/news-release-details/gw-pharmaceuticals-reports-positive-phase-3-pivotal-trial.
   Google Scholar
• EMA. Cannabidiol for the treatment of tuberous sclerosis [Internet]. 2018 [cited 2019 July 8]. Available from: https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu3171959
   Google Scholar
• Gaston TE, Bebin EM, Cutter GR, et al. Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia. 2017;58:1586–1592.
   PubMed Web of Science ®Google Scholar
• Morrison G, Crockett J, Blakey G, et al. A phase 1, open-label, pharmacokinetic trial to investigate possible drug-drug interactions between clobazam, stiripentol, or valproate and cannabidiol in healthy subjects. Clin Pharmacol Drug Dev. 2019 Feb 21. doi: 10.1002/cpdd.665. [Epub ahead of print].
   PubMedGoogle Scholar
• Canevini MP, Kotulska‐Jozwiak K, Curatolo P, et al. Current concepts on epilepsy management in tuberous sclerosis complex. Am J Med Genet Part C Semin Med Genet. 2018;178:299–308.
   PubMed Web of Science ®Google Scholar
• Arya R, Tenney JR, Horn PS, et al. Long-term outcomes of resective epilepsy surgery after invasive presurgical evaluation in children with tuberous sclerosis complex and bilateral multiple lesions. J Neurosurg Pediatr. 2015;15:26–33.
   PubMed Web of Science ®Google Scholar
• McDaniel SS, Rensing NR, Thio LL, et al. The ketogenic diet inhibits the mammalian target of rapamycin (mTOR) pathway. Epilepsia. 2011;52:e7–e11.
   PubMed Web of Science ®Google Scholar
• Major P, Thiele EA. Vagus nerve stimulation for intractable epilepsy in tuberous sclerosis complex. Epilepsy Behav. 2008;13:357–360.
   PubMed Web of Science ®Google Scholar
• Wataya-Kaneda M, Uemura M, Fujita K, et al. Tuberous sclerosis complex: recent advances in manifestations and therapy. Int J Urol. 2017;24:681–691.
   PubMed Web of Science ®Google Scholar
• Citraro R, Leo A, Constanti A, et al. mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis. Pharmacol Res. 2016;107:333–343.
   PubMed Web of Science ®Google Scholar
• Jóźwiak S, Mandera M, Młynarski W. Natural history and current treatment options for subependymal giant cell astrocytoma in tuberous sclerosis complex. Semin Pediatr Neurol. 2015;22:274–281.
   PubMed Web of Science ®Google Scholar
• Roth J, Roach ES, Bartels U, et al. Subependymal giant cell astrocytoma: diagnosis, screening, and treatment. recommendations from the international tuberous sclerosis complex consensus conference 2012. Pediatr Neurol. 2013;49:439–444.
   PubMed Web of Science ®Google Scholar
• Krueger DA, Northrup H, Northrup H, et al. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 international tuberous sclerosis complex consensus conference. Pediatr Neurol. 2013;49:255–265.
   PubMed Web of Science ®Google Scholar
• Franz DN, Belousova E, Sparagana S, et al. Long-term use of everolimus in patients with tuberous sclerosis complex: final results from the EXIST-1 study. Tan M-H, editor. PLoS One. 2016;11:e0158476.
   PubMed Web of Science ®Google Scholar
• Curatolo P, Bjørnvold M, Dill PE, et al. The role of mTOR inhibitors in the treatment of patients with tuberous sclerosis complex: evidence-based and expert opinions. Drugs. 2016;76:551–565.
   PubMed Web of Science ®Google Scholar
• Koenig MK, Butler IJ, Northrup H. Regression of subependymal giant cell astrocytoma with rapamycin in tuberous sclerosis complex. J Child Neurol. 2008;23:1238–1239.
   PubMed Web of Science ®Google Scholar
• Jóźwiak S, Słowińska M, Kotulska K. Management of subependymal giant cell astrocytoma in tuberous sclerosis complex. Polish Arch Intern Med. 2018;129:68–69.
   Google Scholar
• Gupta P. Angiomyolipoma [Internet]. [Cited 2019 July 8]. Available from: http://www.pathologyoutlines.com/topic/kidneytumorangiomyolipoma.html.
   Google Scholar
• Jóźwiak S, Sadowski K, Borkowska J, et al. Liver angiomyolipomas in tuberous sclerosis complex-their incidence and course. Pediatr Neurol. 2018;78:20–26.
   PubMed Web of Science ®Google Scholar
• Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2013;381:817–824.
   PubMed Web of Science ®Google Scholar
• Bissler JJ, Kingswood JC, Radzikowska E, et al. Everolimus long-term use in patients with tuberous sclerosis complex: four-year update of the EXIST-2 study. Eller K, editor. PLoS One. 2017;12:e0180939.
   PubMed Web of Science ®Google Scholar
• Wu R. Lymphangioleiomyomatosis [Internet]. [Cited 2019 July 8]. Available from: http://www.pathologyoutlines.com/topic/lungtumorlymphangioleiomyomatosis.html
   Google Scholar
• Bissler JJ, Franz DN, Frost MD, et al. The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma. Pediatr Nephrol. 2018;33:101–109.
   PubMed Web of Science ®Google Scholar
• Davies DM, de Vries PJ, Johnson SR, et al. Sirolimus therapy for angiomyolipoma in tuberous sclerosis and sporadic lymphangioleiomyomatosis: a phase 2 trial. Clin Cancer Res. 2011;17:4071–4081.
   PubMed Web of Science ®Google Scholar
• Bissler JJ, McCormack FX, Young LR, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008;358:140–151.
   PubMed Web of Science ®Google Scholar
• Dabora SL, Franz DN, Ashwal S, et al. Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF-D levels decrease. Zoccali C, editor. PLoS One. 2011;6:e23379.
   PubMed Web of Science ®Google Scholar
• McCormack FX, Inoue Y, Moss J, et al. Efficacy and safety of sirolimus in Lymphangioleiomyomatosis. N Engl J Med. 2011;364:1595–1606.
   PubMed Web of Science ®Google Scholar
• Kingswood JC, Bissler JJ, Budde K, et al. Review of the tuberous sclerosis renal guidelines from the 2012 consensus conference: current data and future study. Nephron. 2016;134:51–58.
   PubMed Web of Science ®Google Scholar
• Sadowski K, Kotulska-Jóźwiak K, Jóźwiak S. Role of mTOR inhibitors in epilepsy treatment. Pharmacol Rep. 2015;67:636–646.
   PubMed Web of Science ®Google Scholar
• French JA, Lawson JA, Yapici Z, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016;388:2153–2163.
   PubMed Web of Science ®Google Scholar
• FDA approves everolimus for tuberous sclerosis complex-associated partial-onset seizures [Internet]. [Cited 2019 July 8]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-everolimus-tuberous-sclerosis-complex-associated-partial-onset-seizures
   Google Scholar
• EMA: Votubia [Internet]. [Cited 2019 July 8]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/votubia
   Google Scholar
• Franz DN, Budde K, Kingswood JC, et al. Effect of everolimus on skin lesions in patients treated for subependymal giant cell astrocytoma and renal angiomyolipoma: final 4-year results from the randomized EXIST-1 and EXIST-2 studies. J Eur Acad Dermatol Venereol. 2018;32:1796–1803.
   PubMed Web of Science ®Google Scholar
• Sadowski K, Kotulska K, Jóźwiak S. Management of side effects of mTOR inhibitors in tuberous sclerosis patients. Pharmacol Rep. 2016;68:536–542.
   PubMed Web of Science ®Google Scholar
• Koenig MK, Hebert AA, Roberson J, et al. Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin. Drugs R D. 2012;12:121–126.
   PubMedGoogle Scholar
• Jóźwiak S, Sadowski K, Kotulska K, et al. Topical use of mammalian target of rapamycin (mTOR) inhibitors in tuberous sclerosis complex – a comprehensive review of the literature. Pediatr Neurol. 2016;61:21–27.
   PubMed Web of Science ®Google Scholar
• Malissen N, Vergely L, Simon M, et al. Long-term treatment of cutaneous manifestations of tuberous sclerosis complex with topical 1% sirolimus cream: a prospective study of 25 patients. J Am Acad Dermatol. 2017;77:464–472.e3.
   PubMed Web of Science ®Google Scholar
• Wataya-Kaneda M, Tanaka M, Yang L, et al. Clinical and histologic analysis of the efficacy of topical rapamycin therapy against hypomelanotic macules in tuberous sclerosis complex. JAMA Dermatol. 2015;151:722–730.
   PubMed Web of Science ®Google Scholar
• de Vries PJ, Belousova E, Benedik MP, et al. TSC-associated neuropsychiatric disorders (TAND): findings from the TOSCA natural history study. Orphanet J Rare Dis. 2018;13:157.
   PubMed Web of Science ®Google Scholar
• Sato A, Kasai S, Kobayashi T, et al. Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex. Nat Commun. 2012;3:1292.
   PubMed Web of Science ®Google Scholar
• Ehninger D, Han S, Shilyansky C, et al. Reversal of learning deficits in a Tsc2± mouse model of tuberous sclerosis. Nat Med. 2008;14:843–848.
   PubMed Web of Science ®Google Scholar
• Schneider M, de Vries PJ, Schönig K, et al. mTOR inhibitor reverses autistic-like social deficit behaviours in adult rats with both Tsc2 haploinsufficiency and developmental status epilepticus. Eur Arch Psychiatry Clin Neurosci. 2017;267:455–463.
   PubMed Web of Science ®Google Scholar
• Winden KD, Ebrahimi-Fakhari D, Sahin M. Abnormal mTOR activation in autism. Annu Rev Neurosci. 2018;41:1–23.
   PubMed Web of Science ®Google Scholar
• Kilincaslan A, Kok BE, Tekturk P, et al. Beneficial effects of everolimus on autism and attention-deficit/hyperactivity disorder symptoms in a group of patients with tuberous sclerosis complex. J Child Adolesc Psychopharmacol. 2017;27:383–388.
   PubMed Web of Science ®Google Scholar
• Ishii R, Wataya-Kaneda M, Canuet L, et al. Everolimus improves behavioral deficits in a patient with autism associated with tuberous sclerosis: a case report. Neuropsychiatr Electrophysiol. 2015;1:6.
   Google Scholar
• Hwang S-K, Lee J-H, Yang J-E, et al. Everolimus improves neuropsychiatric symptoms in a patient with tuberous sclerosis carrying a novel TSC2 mutation. Mol Brain. 2016;9:56.
   PubMed Web of Science ®Google Scholar
• Mizuguchi M, Ikeda H, Kagitani-Shimono K, et al. Everolimus for epilepsy and autism spectrum disorder in tuberous sclerosis complex: EXIST-3 substudy in Japan. Brain Dev. 2019;41:1–10.
   PubMed Web of Science ®Google Scholar
• Krueger DA, Sadhwani A, Byars AW, et al. Everolimus for treatment of tuberous sclerosis complex-associated neuropsychiatric disorders. Ann Clin Transl Neurol. 2017;4:877–887.
   PubMed Web of Science ®Google Scholar
• Kotulska K, Borkowska J, Jozwiak S. Possible prevention of tuberous sclerosis complex lesions. pediatrics. 2013;132:e239–e242.
   PubMed Web of Science ®Google Scholar
• Jóźwiak S, Kotulska K, Berkowitz N, et al. Safety of everolimus in patients younger than 3 years of age: results from EXIST-1, a randomized, controlled clinical trial. J Pediatr. 2016;172:151–155.e1.
   PubMed Web of Science ®Google Scholar
• Saffari A, Brösse I, Wiemer-Kruel A, et al. Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age – a multicenter retrospective study. Orphanet J Rare Dis. 2019;14:96.
   PubMed Web of Science ®Google Scholar